Solvay shares slip below 250-session floor and decline 2%
The Belgian chemicals company extends its retreat mid-morning, in a declining Paris market. The session comes just days after the upward revision of its annual outlook in the wrong direction and a broker's target adjustment.
A new low breached in a title already below all its averages
The Solvay share is trading at €23.10 and falling 2.04% during the session, after a decline of 7.3% over the week. The price has fallen below €23.58, which marked the low of the last 250 sessions and is now becoming a resistance level. The stock is also below its three moving averages, with gaps of 6.06% on the MA20, 8.66% on the MA50 and 12.13% on the MA200, with an RSI at 26.
The SBF 120 is declining 1.47% at the same time, and the stock ranks at the bottom of the index. The decline of 17.62% over one year illustrates the trend.
An EBITDA target revised downward and analyst targets adjusted
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On October 19, the group lowered its underlying EBITDA 2026 target to €720-740 million. The Middle East conflict and the prolonged shutdown of the Sadara peroxides plant in Saudi Arabia weighed on the third quarter, with an impact of €25 million for the first and €15 million for the second. This range excludes any revenue or compensatory measures from Sadara.
On the analyst consensus side, JP Morgan lowered its target on October 20 from €30.00 to €28.50, with an overweight rating. This target remains more than 23% above the current price. The full quarter results will be published on November 4.
Challenging market environment, excluding potential recovery measures from Sadara, updated guidance reflects Middle East impact
Risks mentioned
Middle East conflict impact of approximately €-25 million on underlying EBITDA in Q3 2026
Continued shutdown of the Peroxide plant at the Sadara complex in Jubail, Saudi Arabia accounted for €-15 million in Q3 2026
Challenging market environment affecting Group performance in Q3 2026
Opportunities identified
Joint venture contractual framework includes mechanisms designed to recover lost profitability from Sadara shutdown
Group exploring all available avenues to mitigate financial impact of shutdown
Transformation program and focus on cash generation and cost savings targets
Outlook / guidance
Expected EBITDA: 730 millions d'euros
Management commentary: In light of these developments, Solvay has reviewed its full-year 2026 guidance. Excluding potential revenue or recovery measures from Sadara for the remainder of 2026, the updated guidance is: Underlying EBITDA between €720 and €740 million
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
